Product logins

Find logins to all Clarivate products below.


Alexandr Ishkin, PhD

Principal Consultant for Discovery and Translational Science Consulting

Alex has over 15 years of experience as a science analyst in systems biology and bioinformatics, working with GeneGo and later Thomson Reuters and Clarivate. His key expertise is in network and pathway analysis of high-throughput molecular data sets, such as DNA-Seq, RNA-Seq, single-cell RNA-Seq, gene expression microarray, proteomics and metabolomics, in the context of drug development.
Alex is an expert in Clarivate’s products MetaBaseTM and CDDI. For over 10 years, he has been responsible for development and maintenance of Clarivate’s metabaseR package that enables efficient access to and bioinformatics analyses of the extensive MetaBaseTM content.

Alex is a program manager and principal software developer for two Clarivate-led precompetitive consortia, CBDD and ABC. The CBDD consortium (Computational Biology for Drug Discovery) was launched in 2013. Within the consortium, Alex developed a toolkit of over 70 advanced network analysis algorithms for drug discovery. Consortium members include Novartis, Pfizer, Sanofi, Roche, Merck, Janssen, Takeda, Boehringer Ingelheim, Eli Lilly, BMS, Abbvie, Biogen, UCB, Regeneron, and Daiichi Sankyo. The ABC (Algorithm Benchmarking Consortium) program is centered around benchmarking bioinformatics tools relevant for drug development research and has been running since 2021. Since its inception, the program helped customers to identify best-performing tools and practices across many areas of bioinformatics research.


arrow_forward
Get in touch with Alexandr

Latest news

News June 17, 2026
Clarivate Releases Journal Citation Reports 2026

Advancing transparency and responsible journal evaluation London, U.K. June 17 2026 — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the release of the Journal…

Partner news June 16, 2026
U.S. News Unveils 2026-2027 Best Global Universities Rankings

Universities in more than 100 countries are evaluated in the newest edition. Washington, D.C. – June 16, 2026 – U.S. News & World Report, the global authority in education rankings…

Partner news
News June 15, 2026
Clarivate’s IPfolio Selected by Mitsubishi Fuso

Managing intellectual property more efficiently with leading data and expertise London, U.K. June 15, 2026. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Mitsubishi…

Related resources

Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization